[A new fixed dose combination of fluticasone and formoterol in a pressurised metered-dose inhaler for the treatment of asthma].
The combination of an inhaled corticosteroid and a long acting beta-2 agonist is indicated for the regular treatment of persistent moderate-to-severe asthmatics whose asthma is not controlled by inhaled corticosteroids and the occasional use of a short acting beta-2 agonist. The aim of this review is to give an overview of the rationale of combining formoterol and fluticasone and to analyze the clinical data concerning a new fixed combination of fluticasone and formoterol in a pressurised metered-dose inhaler with a dose counter (Flutiform(®)) that was approved for the treatment of asthma in France in 2013. The clinical studies provide evidence that combined fluticasone/formoterol is more efficacious than fluticasone or formoterol given alone, and provides similar improvements in lung function to fluticasone (Flixotide(®)) and formoterol (Foradil(®)) administered concurrently. The combination of fluticasone/formoterol gave a more rapid bronchodilatation than the combination fluticasone/salmeterol. As a whole, the combination of fluticasone/formoterol had similar efficacy and tolerability profiles to the combinations of either budesonide/formoterol or fluticasone/salmeterol.
Laboratoire de recherche sur les mécanismes pharmacologiques et moléculaires de l'obstruction bronchique, UPRES EA220, délégation à la recherche clinique et à l'innovation, pôle des maladies respiratoires, hôpital Foch, 11, rue Guillaume-Lenoir, 92150 Suresnes, France. Electronic address: p.devillier@hopital-foch.org.
P
P
Devillier
Laboratoire de recherche sur les mécanismes pharmacologiques et moléculaires de l'obstruction bronchique, UPRES EA220, délégation à la recherche clinique et à l'innovation, pôle des maladies respiratoires, hôpital Foch, 11, rue Guillaume-Lenoir, 92150 Suresnes, France; Pôle des maladies respiratoires, hôpital Foch, 92150 Suresnes, France.
H
H
Salvator
Laboratoire de recherche sur les mécanismes pharmacologiques et moléculaires de l'obstruction bronchique, UPRES EA220, délégation à la recherche clinique et à l'innovation, pôle des maladies respiratoires, hôpital Foch, 11, rue Guillaume-Lenoir, 92150 Suresnes, France.
S
S
Grassin-Delyle
Laboratoire de recherche sur les mécanismes pharmacologiques et moléculaires de l'obstruction bronchique, UPRES EA220, délégation à la recherche clinique et à l'innovation, pôle des maladies respiratoires, hôpital Foch, 11, rue Guillaume-Lenoir, 92150 Suresnes, France.
E
E
Naline
Laboratoire de recherche sur les mécanismes pharmacologiques et moléculaires de l'obstruction bronchique, UPRES EA220, délégation à la recherche clinique et à l'innovation, pôle des maladies respiratoires, hôpital Foch, 11, rue Guillaume-Lenoir, 92150 Suresnes, France.
C
C
Advenier
Service de pneumologie, hôpitaux universitaires Paris Centre, HIA du Val-de-Grâce, 75005 Paris, France.
N
N
Roche
D000280:Administration, Inhalation; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives; D000730:Androstadienes / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D004338:Drug Combinations; D004983:Ethanolamines / Q000008:administration & dosage*; D000068298:Fluticasone; D000068297:Fluticasone-Salmeterol Drug Combination; D000068759:Formoterol Fumarate; D006801:Humans; D036501:Metered Dose Inhalers
D000730:Androstadienes; D001993:Bronchodilator Agents; D004338:Drug Combinations; D004983:Ethanolamines; D000068297:Fluticasone-Salmeterol Drug Combination; D000068298:Fluticasone; D000420:Albuterol; D000068759:Formoterol Fumarate
Association fixe; Asthma; Asthme; Combined treatment; Fluticasone; Formoterol; Formotérol